Through an in vivo study, we have shown that administering an M13 filamentous bacteriophage-based vaccine in mice induces an anti-MAGE-A1 antibody response and generates antigen-specific cytotoxic T lymphocytes (CTLs) capable of targeting and eliminating tumor cells. The gene discussed is MAGEA1; the disease is neoplasm.